Healthcare Global Enterprises · NSE: HCG · BSE: 539787
Q2 FY21 results · Jul–Sep 2020
Healthcare Global Enterprises reported revenue from operations of ₹247.92 crore (down 11.0% from Q2 FY20) and net loss of ₹26.56 crore for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 247.92 | 278.46 | −11.0% | 193.46 | +28.2% |
| Other income | 4.01 | 1.52 | +163.8% | 2.72 | +47.4% |
| Total income | 251.93 | 279.98 | −10.0% | 196.18 | +28.4% |
| Profit before share of associates & JVs and tax | (32.29) | (22.02) | Loss widened | (54.71) | Loss narrowed |
| Share of profit/(loss) of associates & JVs | 0.44 | (4.89) | (1.92) | ||
| Net profit for the period | (26.56) | (25.26) | Loss widened | (45.61) | Loss narrowed |
| Attributable to shareholders of the company | (22.29) | (22.28) | Loss widened | (39.75) | Loss narrowed |
| EPS, basic (₹) | (1.94) | (2.51) | not comparable | (4.48) | not comparable |
| Net margin (%) | -10.7 | -9.1 | -23.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 145.56 | 173.71 | −16.2% | 121.90 | +19.4% |
| Other income | 5.56 | 2.36 | +135.6% | 3.41 | +63.0% |
| Total income | 151.12 | 176.07 | −14.2% | 125.31 | +20.6% |
| Profit before tax | (12.23) | (5.02) | Loss widened | (28.33) | Loss narrowed |
| Net profit for the period | (6.58) | (3.47) | Loss widened | (18.73) | Loss narrowed |
| EPS, basic (₹) | (0.57) | (0.39) | not comparable | (2.11) | not comparable |
| Net margin (%) | -4.5 | -2.0 | -15.4 |
Consolidated
- Filed with BSE
- 19 Nov 2020, 19:09 IST
- Board meeting
- 12 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Nov 2020, 19:09 IST
- Board meeting
- 12 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE